Galmed Pharmaceuticals
GLMD
31 hedge funds and large institutions have $34M invested in Galmed Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
13% more capital invested
Capital invested by funds: $30.1M → $34M (+$3.91M)
0% more funds holding
Funds holding: 31 → 31 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.01% less ownership
Funds ownership: 0.17% → 0.15% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$712K |
| 2 |
Renaissance Technologies
New York
|
+$231K |
| 3 |
Morgan Stanley
New York
|
+$220K |
| 4 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$143K |
| 5 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$2.66M |
| 2 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$788K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$696K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$109K |
| 5 |
WAM
Wealthspire Advisors (Maryland)
Potomac,
Maryland
|
-$65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $26K | +$22.3K | +26 | New |
|
|
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $5.78K | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| $4K | +$3.44K | +4 | New |
|
|
BCM
29
Bourgeon Capital Management
Darien,
Connecticut
| $3K | – | – | – |
|
|
FHA
30
Flagship Harbor Advisors
Boston,
Massachusetts
| $2K | – | – | – |
|
|
RFA
31
Reilly Financial Advisors
La Mesa,
California
| $1K | – | – | – |
|
|
FMBTD
32
First Midwest Bank Trust Division
Joliet,
Illinois
| – | -$788K | -916 | Closed |
|
|
KCM
33
Knoll Capital Management
Miami,
Florida
| – | -$696K | -809 | Closed |
|
|
34
Marshall Wace
London,
United Kingdom
| – | -$109K | -127 | Closed |
|
|
WAM
35
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| – | -$65K | -75 | Closed |
|
36
US Bancorp
Minneapolis,
Minnesota
| – | -$9K | -10 | Closed |
|
37
Bank of America
Charlotte,
North Carolina
| – | -$2K | -3 | Closed |
|
|
CG
38
Cutler Group
San Francisco,
California
| – | -$859 | -1 | Closed |
|
GLMD Hedge Fund Activity: Q4 2019 in Review
31 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2019, worth a combined $34M — up 13% from $30.1M a quarter earlier.
Fund positioning in GLMD was balanced in Q4 2019: 7 funds opened new positions, 7 closed out, 8 added to existing stakes and 6 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $712K. The largest seller was 683 Capital Management, cutting an estimated $2.66M.
- 31 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $34M of Galmed Pharmaceuticals stock for Q4 2019, up 13% quarter-over-quarter.
- 7 funds opened new Galmed Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2019 was Raymond James & Associates, an estimated $712K added.
- The largest Galmed Pharmaceuticals seller in Q4 2019 was 683 Capital Management, an estimated $2.66M sold.
Based on aggregated 13F filings for Q4 2019.